-
2023-509392-17-00
5
Relapsed Acute Lymphoblastic Leukemia (ALL)
-
2024-511114-20-00
5
Craniopharyngioma
-
2024-514243-29-01
5
This is a prospective, French, multicenter, open-label, design, strati
-
2024-515340-23-00
4
Colon cancer
-
2024-516167-86-00
5
Patients referred for an isolated or a combined surgical correction of
-
2024-519655-28-00
5
Premenopausal patients with high-risk HR-positive/HER2-negative breast
-
2024-519818-31-01
5
Endometrial Cancer
Advanced, Recurrent, Metastatic, or Primary Unresec
-
2024-520414-21-00
5
Adult patients with a LVOS with large core within 9 hours of symptoms
-
2025-520632-42-00
5
axial or predominantly axial SpA with or without psoriasis
-
2025-521371-31-00
4
Sepsis
-
2025-521619-37-00
5
Patients ≥75 years old with cT3/T4 rectal adenocarcinoma eligible to r
-
2025-521909-40-00
4
Patients with metastatic or locally advanced HER2-low triple-negative
-
2025-522791-92-00
5
Neoplasm Metastasis
-
2025-522870-35-00
4
Lichen
-
2025-523094-42-00
5
Hirschsprung's disease
-
2025-523259-72-00
5
Hidradenitis Suppurativa (HS)
-
2025-523586-18-00
5
Non-Small Cell Lung Cancer
-
2025-524408-30-01
5
Metastatic hormone-sensitive prostate cancer
-
2024-516527-13-00
11
2026-05-27
Kidney transplantation
-
2025-521865-29-00
4
2026-04-30
moderate-to-severe hidradenitis suppurativa
-
2025-520466-22-00
5
2026-04-29
Advanced Platinum-resistant Epithelial Ovarian Cancer
-
2025-520979-13-00
5
2025-12-18
Patients with HR+ HER2- early breast cancer at intermediate risk of re
-
2024-516906-47-00
10
2025-11-28
Locally Advanced or Metastatic Urothelial Carcinoma
-
2024-520107-12-00
5
2025-09-03
Hidradenitis Suppurativa // Prurigo Nodularis // Vitiligo